Plain-English translation of NCT05888532 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Prostate Cancer research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This is one of the first times this treatment has been tested in people.
This trial is testing a new imaging agent called 64Cu-GRIP B, which is a radioactive tracer that can be injected into your body to help doctors see where cancer cells are located using PET scans. The study wants to understand how safe this medication is, how it behaves in the body, and whether it can help predict how well cancer treatments will work for you.
Standard imaging scans sometimes miss small tumors or can't tell if a tumor is responding to treatment. This new medication is designed to light up cancer cells in a way that current imaging cannot, potentially helping doctors catch cancer earlier and monitor treatment response more accurately.
You likely qualify if…
You likely don't qualify if…
You will receive an injection of the radioactive tracer and then have PET imaging scans at multiple time points (ranging from 30 minutes to 24 hours after injection). If you are in certain groups, you may have scans before starting immunotherapy, after 8 weeks of treatment, and again if your cancer progresses. Some participants may also have blood samples taken and undergo tumor biopsies. The entire study involvement may span several months depending on your treatment schedule.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
United States